# OnCo record paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016" ;
schema:name "STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis"@en ;
schema:alternateName "STOpCaP"@en, "Vale 2016 docetaxel meta-analysis"@en, "adaptive meta-analysis prostate docetaxel"@en ;
schema:description "Three trials of chemotherapy at the start of hormone therapy had reported, two positive and one negative. Pooling them showed the treatment does work in metastatic disease, improving four-year survival by about nine percent, and that zoledronic acid does not."@en ;
schema:url ;
schema:dateModified "2026-09-25"^^xsd:date ;
schema:citation , ;
onco:tag "prostate-evidence" ;
schema:sameAs ;
schema:datePublished "2016"^^xsd:gYear ;
schema:author "Vale CL, Burdett S, Rydzewska LHM, et al." ;
onco:related , , , ;
onco:cancers , ;
onco:sections , ;
onco:drugs , ;
onco:terms , , ;
onco:people , , ;
onco:bottlenecks , , ;
onco:journals .